CA2989522C - Pharmaceutical compositions and methods for treating ocular inflammatory conditions - Google Patents
Pharmaceutical compositions and methods for treating ocular inflammatory conditions Download PDFInfo
- Publication number
- CA2989522C CA2989522C CA2989522A CA2989522A CA2989522C CA 2989522 C CA2989522 C CA 2989522C CA 2989522 A CA2989522 A CA 2989522A CA 2989522 A CA2989522 A CA 2989522A CA 2989522 C CA2989522 C CA 2989522C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- administration
- pharmaceutical composition
- pharmaceutically acceptable
- ocular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562189813P | 2015-07-08 | 2015-07-08 | |
| US62/189,813 | 2015-07-08 | ||
| PCT/IB2016/054073 WO2017006272A1 (en) | 2015-07-08 | 2016-07-07 | Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2989522A1 CA2989522A1 (en) | 2017-01-12 |
| CA2989522C true CA2989522C (en) | 2022-10-18 |
Family
ID=56373100
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2989522A Active CA2989522C (en) | 2015-07-08 | 2016-07-07 | Pharmaceutical compositions and methods for treating ocular inflammatory conditions |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10413535B2 (https=) |
| EP (1) | EP3319639B1 (https=) |
| JP (2) | JP6752276B2 (https=) |
| KR (2) | KR20220062688A (https=) |
| CN (1) | CN107921136A (https=) |
| AU (1) | AU2016290197B2 (https=) |
| BR (1) | BR112018000112A2 (https=) |
| CA (1) | CA2989522C (https=) |
| CL (1) | CL2018000057A1 (https=) |
| ES (1) | ES2835274T3 (https=) |
| HK (1) | HK1247120A1 (https=) |
| IL (2) | IL256770B (https=) |
| MA (2) | MA42016A1 (https=) |
| MX (1) | MX385229B (https=) |
| MY (1) | MY187552A (https=) |
| PL (1) | PL3319639T3 (https=) |
| RU (1) | RU2018103940A (https=) |
| TN (1) | TN2017000538A1 (https=) |
| UA (1) | UA123728C2 (https=) |
| WO (1) | WO2017006272A1 (https=) |
| ZA (1) | ZA201708601B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018165218A1 (en) * | 2017-03-09 | 2018-09-13 | Allysta Pharmaceuticals, Inc | Peptides for dry eye disease |
| EP3624773A4 (en) * | 2017-05-19 | 2021-04-07 | Ocugen, Inc. | OPHTHALMIC COMPOSITIONS AND METHOD OF USE |
| KR102659859B1 (ko) | 2018-10-30 | 2024-04-25 | 길리애드 사이언시즈, 인코포레이티드 | 알파4β7 인테그린의 억제를 위한 화합물 |
| AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| EP4541422A3 (en) | 2018-10-30 | 2025-06-25 | Gilead Sciences, Inc. | Quinoline derivatives as alpha4beta7 integrin inhibitors |
| CN112969700B (zh) | 2018-10-30 | 2024-08-20 | 吉利德科学公司 | 作为α4β7整合素抑制剂的咪唑并吡啶衍生物 |
| MX2022001062A (es) * | 2019-07-26 | 2022-02-14 | Allegro Pharmaceuticals Llc | Peptidos para el tratamiento de degeneracion macular no exudativa y otros trastornos del ojo. |
| KR102908219B1 (ko) | 2019-08-14 | 2026-01-08 | 길리애드 사이언시즈, 인코포레이티드 | 알파 4 베타 7 인테그린의 저해용 화합물 |
| KR20230110514A (ko) * | 2020-10-21 | 2023-07-24 | 아주라 오프탈믹스 엘티디 | 안구 장애의 치료를 위한 화합물 및 방법 |
| KR102391198B1 (ko) * | 2021-08-27 | 2022-04-27 | 한림제약(주) | 리피테그라스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 수용액 형태의 점안액 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9828074D0 (en) * | 1998-12-18 | 1999-02-17 | Glaxo Group Ltd | Therapeutically useful compounds |
| GB0014892D0 (en) | 2000-06-16 | 2000-08-09 | Glaxo Group Ltd | Novel pharmaceutical formulation |
| DK2444079T3 (en) | 2005-05-17 | 2017-01-30 | Sarcode Bioscience Inc | Compositions and Methods for the Treatment of Eye Diseases |
| WO2007056457A2 (en) * | 2005-11-09 | 2007-05-18 | Combinatorx, Incorporated | Methods, compositions, and kits for the treatment of medical conditions |
| US20130217657A1 (en) | 2011-12-21 | 2013-08-22 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
-
2016
- 2016-07-07 ES ES16736636T patent/ES2835274T3/es active Active
- 2016-07-07 CA CA2989522A patent/CA2989522C/en active Active
- 2016-07-07 PL PL16736636T patent/PL3319639T3/pl unknown
- 2016-07-07 JP JP2018520045A patent/JP6752276B2/ja not_active Expired - Fee Related
- 2016-07-07 UA UAA201800954A patent/UA123728C2/uk unknown
- 2016-07-07 BR BR112018000112-0A patent/BR112018000112A2/pt not_active Application Discontinuation
- 2016-07-07 CN CN201680040066.0A patent/CN107921136A/zh active Pending
- 2016-07-07 KR KR1020227015200A patent/KR20220062688A/ko not_active Ceased
- 2016-07-07 MY MYPI2017001928A patent/MY187552A/en unknown
- 2016-07-07 TN TNP/2017/000538A patent/TN2017000538A1/en unknown
- 2016-07-07 RU RU2018103940A patent/RU2018103940A/ru unknown
- 2016-07-07 WO PCT/IB2016/054073 patent/WO2017006272A1/en not_active Ceased
- 2016-07-07 EP EP16736636.8A patent/EP3319639B1/en active Active
- 2016-07-07 KR KR1020187003454A patent/KR102440162B1/ko active Active
- 2016-07-07 AU AU2016290197A patent/AU2016290197B2/en not_active Ceased
- 2016-07-07 MA MA42016A patent/MA42016A1/fr unknown
- 2016-07-07 HK HK18106821.2A patent/HK1247120A1/zh unknown
- 2016-07-07 MX MX2017017163A patent/MX385229B/es unknown
- 2016-07-07 US US15/742,867 patent/US10413535B2/en not_active Expired - Fee Related
-
2017
- 2017-12-18 ZA ZA2017/08601A patent/ZA201708601B/en unknown
-
2018
- 2018-01-07 IL IL256770A patent/IL256770B/en active IP Right Grant
- 2018-01-08 CL CL2018000057A patent/CL2018000057A1/es unknown
- 2018-02-08 MA MA44935A patent/MA44935A1/fr unknown
-
2019
- 2019-09-12 US US16/569,465 patent/US10751334B2/en not_active Expired - Fee Related
-
2020
- 2020-04-06 JP JP2020068158A patent/JP2020121985A/ja active Pending
- 2020-07-13 US US16/927,825 patent/US20200405703A1/en not_active Abandoned
-
2021
- 2021-02-11 IL IL280827A patent/IL280827A/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10751334B2 (en) | Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions | |
| US20220184057A1 (en) | Combination treatment of ocular inflammatory disorders and diseases | |
| EP3525799B1 (en) | Method for establishing, restoring, and preserving homeostasis of the ocular surface | |
| JP2020502197A (ja) | ドライアイ疾患の治療のための眼科用組成物 | |
| SA521430043B1 (ar) | صياغات من المركب 4-(7- هيدروكسي-2- أيزوبروبيل-4- أوكسو-4h- كوينازولين-3- يل) - بنزونيتريل | |
| US20170290888A1 (en) | Compositions and Methods for Treating Inflammatory Conditions of the Ocular Surface | |
| US20250276004A1 (en) | High molecular weight hyaluronic acid for treatment and prevention of severe ocular surface disease | |
| EP4167965A1 (en) | Use of high molecular weight hyaluronic acid as ocular transporting vehicle | |
| OA19750A (en) | Pharmaceutical compositions comprising an integrin alpha4 antagonist for use in treating ocular inflammatory conditions. | |
| CN107106566A (zh) | 晶状体硬化抑制剂 | |
| EP4640702A1 (en) | Use of alpha-2,6-sialylated immunoglobulin in preventing or treating dry eye syndrome or inflammatory eye diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20201014 |
|
| H11 | Ip right ceased following rejected request for revival |
Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED Effective date: 20250108 |